Our journey began in 2014, deep in the jungles of Koraput, one of the remotest and most underserved districts of Odisha, India. It was here that we discovered a breakthrough in malaria treatment from natural extracts — a potent Phytopharmaceutical formulation commercially launched as Opunika®

Opunika® is a breakthrough anti-malarial medicine comprising highly standardised natural extract, uniquely developed in India, validated in European laboratories, and field-tested in Africa. It is the only commercially launched medicine for malaria, derived from a wild cultivar of Punica granatum rind, offering both therapeutic and preventive efficacy against P.vivax and P.falciparum — the two most common and dangerous forms of malaria.

With a bold vision to eradicate malaria by 2030, we established Consytel®  Life Sciences Pvt Ltd. in 2017. Our mission is to eliminate malaria and dengue globally through innovative, mass deployable, evidence-based botanical drugs combined with AI-powered, IoT-enabled vector surveillance and control devices.

As a next-generation Phytopharmaceutical company in India, we are committed to transforming public health through affordable malaria prevention therapy and holistic wellness solutions. Our approach bridges the gap between traditional knowledge and modern science, offering innovative solutions for malaria where conventional medicine falls short.

We are not just creating innovative products — we are changing the way of living.

Consytel®  Life Sciences Pvt Ltd. is an early-traction biotech startup in India, focused on addressing therapeutic areas not adequately served by modern medicine. Our mission is to develop evidence-backed botanical drugs that offer safe, effective therapy options for unmet clinical needs

One of our core R&D priorities is the eradication of Vector-Borne Diseases, especially malaria and dengue. Our work in this space has been recognized and funded by BIRAC (Government of India). We are proud to be at the forefront of developing Phytopharmaceutical based anti- malarial formulation for therapeutic as well as prophylactic needs that are both affordable and accessible.

In addition to our flagship offering for malaria, we are advancing research in biopharmaceuticals targeting allergy and immunology, developing functional nutraceuticals aimed at promoting healthy ageing and delaying the onset of chronic diseases.

Our deep expertise in vector biology and pharmacology has led to the creation of an AI-driven, IoT-enabled device for smart vector control – a game-changing innovation in malaria prevention and public health.

We are proudly incubated at the Atal Incubation Centre – CCMB, Hyderabad, one of India’s premier deep life science incubators, where we continue to push the boundaries of phytopharmaceuticals and digital health innovation.